San Diego, CA — October 16, 2025 — Leads & Copy — Endure Biotherapeutics, Inc. has been awarded a research grant from the National PKU Alliance (NPKUA) to support the development of a novel Engineered Native Bacteria (ENB) candidate for the treatment of Phenylketonuria (PKU), a rare genetic disorder. The funding will go to the Zarrinpar Lab at UCSD.
Amir Zarrinpar, MD, PhD, founder and Chief Medical Officer of Endure Bio and Professor of Medicine at UC San Diego, expressed gratitude for the NPKUA’s support, highlighting the potential of their ENB platform technology to provide a full-spectrum treatment for PKU. Mark S. Wilson, CEO of Endure Bio, added that the grant will enable preclinical efficacy studies, with the aim of rapid advancement toward clinical development.
Endure Bio’s ENB platform allows for genetic modification of beneficial gut bacteria to deliver therapeutic functions, offering an advantage over earlier microbiome therapeutics. The company is developing a pipeline of ENB-based therapeutics for diseases including Familial Adenomatous Polyposis (FAP), PKU, and age-related metabolic disorders.
The National PKU Alliance (NPKUA) is a leading nonprofit dedicated to improving the lives of those affected by PKU through advocacy, education, and research funding.
Endure Biotherapeutics, Inc. is a preclinical-stage biotechnology company focused on developing engineered, engraftable live biotherapeutics for genetic and chronic diseases.
Contact:
Mark S. Wilson
Chief Executive Officer
Endure Biotherapeutics, Inc.
Email: info@endurebio.com
Source: Endure Biotherapeutics, Inc.
